Three take­aways and three burn­ing ques­tions for Chris Viehbacher's cost-cut­ting fu­ture at Bio­gen

Chris Viehbach­er has un­veiled his most dra­mat­ic move yet as Bio­gen’s CEO, aim­ing to save $1 bil­lion per year with a cost-cut­ting plan to chart a path back to growth for the biotech gi­ant.

On Tues­day’s earn­ings call, Viehbach­er an­nounced a “re­turn to growth” plan that in­cludes low­er­ing the head­count by 1,000 em­ploy­ees over the next cou­ple of years.  Viehbach­er said he hopes to make Bio­gen nim­bler and more cap­i­tal-ef­fi­cient through the changes, in­clud­ing look­ing be­yond neu­rol­o­gy for safer pipeline bets. The im­me­di­ate in­vestor re­ac­tion ap­peared un­con­vinced as Bio­gen’s stock price $BI­IB fell by near­ly 5% af­ter the mar­ket opened.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER